New research has discovered certain weight-loss medications could be associated with an increased risk of serious eye conditions, and even vision loss.

Two studies, published in JAMA, analyzed how semaglutide and tirzepatide — which include popular drugs like Ozempic, Wegovy, Mounjaro and Zepbound — impacted eye health in Americans with type 2 diabetes over a two-year period.

One study found a modest risk of developing non-arteritic anterior ischaemic optic neuropathy (NAOIN) – a rare eye condition that can lead to sudden vision loss due to lack of blood flow – in association with semaglutide and tirzepatide.

POPULAR WEIGHT-LOSS MEDICATION COULD RELIEVE PAINFUL ARTHRITIS SYMPTOMS, DOCTORS REPORT

Out of more than 159,000 study participants with type 2 diabetes, 35 developed NAIO

See Full Page